Clinical-stage biotech developing antibody-drug conjugates for cancer.
Founders
Lars Henning Engelholm(Denmark · ♂)— A cancer researcher at Copenhagen's Finsen Laboratory, Engelholm co-founded Adcendo to translate his lab's discoveries on the uPARAP receptor into antibody-drug conjugate cancer therapies.
Niels Behrendt(Denmark · ♂)— A scientific co-founder and Finsen Laboratory professor whose research underpins Adcendo, Behrendt spun the company out of the University of Copenhagen to develop targeted ADC cancer drugs.
Christoffer Nielsen(DK · ♂)— A scientist from the Finsen Laboratory and University of Copenhagen, Nielsen co-founded Adcendo to translate uPARAP receptor research into antibody-drug conjugates for cancer.
Henrik Stage(DK · ♂)— A biotech entrepreneur, Stage co-founded Adcendo to commercialize the University of Copenhagen spin-out's antibody-drug conjugate pipeline.
Team & hubs
In the network
Shares the most investors with (number = shared investors):